Background and Aims: Prophylactic azathioprine (AZA) is efficacious in preventing postoperative Crohn's disease (CD) recurrence. However, it is unknown whether AZA should be started immediately after surgery. We compared the efficacy of systematic vs endoscopy-driven AZA in preventing CD recurrence at week 102. Methods: This prospective, multicentre trial included CD patients undergoing curative resection with ileocolonic anastomosis and at higher risk of recurrence. Patients were randomized to systematic AZA initiated ≤2 weeks from surgery, or endoscopy-driven AZA in which therapy was only initiated in case of endoscopic recurrence (Rutgeerts' score ≥i2) at weeks 26 or 52 following surgery. The primary endpoint was endoscopic remission (i0-i1) at week 102. Secondary endpoints included complete endoscopic remission (i0) and clinical remission. Results: The study was prematurely stopped due to slow recruitment. Between 2005 and 2011, 63 patients (28 male, median age 36 years) were randomized to systematic (n = 32) or endoscopydriven AZA (n = 31). Twenty-one patients withdrew prematurely (8 clinical recurrence, 6 adverse reactions to AZA, 7 patient's preference). In the endoscopy-driven AZA group, 14 patients had to initiate AZA (11 at week 26, 3 at week 52). Endoscopic remission was achieved by 50% in the systematic and 42% in the endoscopy-driven AZA group (p = 0.521). No difference in secondary endpoints was found. Conclusions: Systematic AZA therapy in patients at higher risk of postoperative CD recurrence is not superior to endoscopy-driven treatment. Early postoperative endoscopic evaluation between weeks 26 and 52 seems most appropriate to guide further therapy, but larger studies are warranted. (ClinicalTrials.gov NCT02247258.) 
Introduction
Recurrence of ileal Crohn's disease (CD) after surgically induced disease remission occurs in virtually all patients. Endoscopic recurrence was observed in >70% of patients at 1 year, and the need for a new surgical or endoscopic intervention has been reported to vary between 15 and 65% after 10 years.
1,2 Endoscopic recurrence usually precedes symptom recurrence by several years and has been proposed as a marker predicting disease relapse. A five-grade endoscopic severity score for recurrent ileal disease has been implemented in clinical trials. 1 Although endoscopic recurrence does not necessarily imply that patients have symptom recurrence, the large need for repeated surgery indicates that lesions gradually developing after surgical remission lead to fibrostenosis or other complications. Risk factors for early recurrence have been incompletely defined, but active smoking, perforating disease and predominant ileal disease are considered to accelerate postoperative relapse. 3 Since surgical remission of ileal disease is only temporary, several medical therapeutic strategies aimed at reducing or retarding recurrence have been evaluated. Most treatments, such as mesalamine or budesonide, have shown little or no benefit. 4, 5 Nitroimidazole antibiotics are effective in the short term but toxicity associated with long-term use precludes maintenance therapy. 6, 7 A recent meta-analysis suggested that the purine analogues azathioprine (AZA) and mercaptopurine (MP) are more efficacious than placebo in preventing both clinical and endoscopic postoperative recurrence, but are also associated with a higher rate of adverse events. 8 In the landmark study by Regueiro et al., 9 infliximab (IFX) was efficacious in preventing both endoscopic and histological recurrence of CD, but the proportion of patients in clinical remission was not significantly higher than with placebo. The outcome data of the placebo-controlled PREVENT trial evaluating the efficacy of IFX in preventing postoperative clinical recurrence are still awaited. 10 A secondary analysis of the recently published POCER trial showed superiority of postoperative prophylactic therapy with adalimumab over azathioprine in preventing endoscopic recurrence at 6 months in high-risk patients. 11 Most of these studies started in the immediate postoperative phase and did not incorporate risk stratification based on early endoscopic recurrence. Furthermore, it is largely unknown whether immediate initiation of immune-suppressive agents postoperatively is required for maintaining clinical remission, or whether disease remission can be induced if immune-suppressive agents are initiated only upon severe endoscopic recurrence. Indeed, adequately dosed purine analogues have been shown to induce longstanding clinical disease remission in >50% of patients with active inflammatory CD. Furthermore, successful AZA therapy was accompanied by complete mucosal healing in 70% of patients. 12 Therefore, clinicians currently adopt both strategies of early introduction of immune-suppressive agents and of delayed introduction upon clinical or endoscopic recurrence. Immediate introduction of immune-suppressive agents after surgery is often advocated in patients with a high risk of early relapse (previous ileal resections, perforating disease, active smoking). 13 Data from the POCER study suggest that prophylactic postoperative therapy according to clinical risk of recurrence and adjusted to postoperative endoscopic findings is superior to conventional therapy alone. 11 However, the design of the trial makes it difficult to directly compare immediate prophylactic with delayed, endoscopy-driven therapy.
We evaluated whether the prevention of postoperative clinical recurrence with systematic initiation of AZA in the immediate postoperative phase was superior to a delayed, endoscopy-driven introduction of AZA upon endoscopic disease recurrence.
Materials and Methods

Patients
Patients undergoing curative resection with ileocolonic anastomosis for CD were invited between October 2005 and April 2012 to participate in this multicentre trial, which was sponsored by the International Organization for the study of Inflammatory Bowel Disease (IOIBD). Patients were recruited in four different European referral centres. The diagnosis of CD had to be confirmed at least 4 months prior to surgery based on radiology and/or endoscopy. Patients were eligible if they had least one risk factor for postoperative relapse, including (1) active inflammatory disease with C-reactive protein (CRP) elevation above 10 mg/L or the use of antibiotics, steroids or biological therapy including anti-TNF therapy for active ileal disease within 2 months before surgery; (2) perforating disease, defined as the presence of entero-enteric or enterocutaneous fistulas or a perivisceral abscess formation within 2 months before surgery; (3) previous ileocolonic resection; (4) active smoking; and (5) age <30. Patients had to be between 16 and 75 years old at screening and had to understand and sign a written informed consent form. Women of childbearing age needed to have a negative pregnancy test and had to use adequate birth control measures during the whole study.
Exclusion criteria included known intolerance of purine analogues or known risk of bone marrow suppression based on thiopurine methyltransferase (TPMT) profile, liver test abnormalities [>2-fold upper limit of normal (ULN)], leucopenia (<3000 white blood cells 10 9 /L, <1500 neutrophils 10 9 /L), thrombocytopenia (<50 000 platelets/mm 3 ), severe renal, pulmonary or cardiac disease, ongoing alcohol or substance abuse, and recent or ongoing infectious disease or malignancy. Former use of thiopurine analogues or biologicals was permitted.
Ethical considerations
The trial was approved by the central medical ethics committee at the University of Leuven, Belgium, and at all participating centres. All authors had access to the study data and reviewed and approved the final manuscript.
Treatment arms
Patients were randomized 1:1 and balanced for age using a central computer-based randomization system. As depicted in Figure 1 , patients randomized to the systematic AZA group received 2.0-2.5 mg/kg AZA within 14 days from surgery and throughout 102 weeks. Patients randomized to the endoscopy-driven AZA group received no CD-specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score ≥i2), AZA was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and AZA was started if there was endoscopic recurrence. If no endoscopic recurrence was observed, no CD-specific treatment was given until week 102.
Concomitant therapies
Prednisolone or other corticosteroids (including budesonide) had to be tapered and discontinued within 6 weeks after surgery. Aminosalicylates, probiotics and antibiotics had to be discontinued at the time of surgery. During the study, antibiotics were allowed for intercurrent infections or perianal CD, but not for active luminal CD. Methotrexate, biological agents, thalidomide, ciclosporin and tacrolimus had to be stopped at surgery. Any investigational agent had to be discontinued at least 8 weeks and 5 half-lives prior to inclusion. Antidiarrhoeals (e.g. loperamide, diphenoxylate, cholestyramine), antispasmodics and topical treatment for anorectal involvement were permitted.
Study procedures
Patients underwent clinical evaluation with physical examination and biochemical analysis at baseline and weeks 12, 26, 34, 52, 62, 80 and 102 after randomization. Stool frequency, abdominal pain and presence of extra-intestinal manifestations were recorded. Physical examination included body weight, blood pressure, body temperature and abdominal examination. Laboratory assessments included peripheral blood counts, CRP, alkaline phosphatase, bilirubin, serum glutamate oxaloacetate transaminase, serum glutamate pyruvate transaminase, lipase, creatinine and urea levels. All patients underwent an ileocolonoscopy at week 26 and 102, with determination of Rutgeerts' score for ileal recurrence of CD. In those patients randomized to the endoscopy-driven AZA group and still in endoscopic remission (<i2) at week 26, an extra ileocolonoscopy was performed at week 52. Endoscopists were blinded to treatment allocation and time interval from surgery. Besides ileocolonoscopy, barium smallbowel X-ray series were performed in all patients at 102 weeks or at the time of clinical relapse. Adverse events and concomitant medication were recorded at every scheduled or unscheduled visit.
Adverse events were recorded as mild, moderate, severe or lifethreatening and the relationship with the study drugs was assessed as not related, possibly related, probably related or definitely related. All events were followed to satisfactory resolution and/or stabilization. All actions taken were recorded.
Several adverse events might be (dose-dependently) related to treatment with AZA. An elevation of transaminases up to 5-fold the ULN and of alkaline phosphatase up to 2-fold the ULN were allowed, and did not lead to a change in therapy or discontinuation. More severe liver test abnormalities led to discontinuation of therapy and study participation. If the total white count was <3000 10 9 /L or the platelet count was <50 000/mm 3 , AZA had to be interrupted. Outside the study protocol, AZA could be reintroduced at a lower dose. Patients who developed biochemically confirmed pancreatitis or a severe systemic viral disease had to discontinue AZA. In patients with persisting nausea and dyspepsia, AZA could be replaced by MP at a dose of 1.0-1.5 mg/kg.
Endpoints
The primary endpoint was the proportion of patients with endoscopic remission (postoperative Rutgeerts' endoscopic score i0 or i1) at 102 weeks in the delayed, endoscopy-driven AZA treatment group and the systematic AZA treatment group. Secondary endpoints included (1) the percentage of patients with a Rutgeerts' score of i0 at 102 weeks, (2) the percentage of patients with a Rutgeerts' score of i0-i2 at 102 weeks, (3) the percentage of patients in clinical remission [CD activity index (CDAI) <150] at 102 weeks, (4) the percentage of patients in clinical remission (CDAI <150) throughout the trial, and (5) the percentage of patients with radiological remission at 102 weeks. Finally, we also evaluated the evolution of CDAI throughout the 102-week study period.
Sample size calculation and statistical analysis
For this superiority study, the null hypothesis was that an equal proportion of patients in the endoscopy-driven AZA group would have endoscopic recurrence at week 102 compared with the systematic AZA group. We assumed that 45% of subjects in the endoscopydriven group and 20% of patients in the systematic AZA group would have endoscopic recurrence at week 102. In the endoscopydirected AZA group, we expected that 85% would have endoscopic recurrence at week 26 or 52, that 50% of these patients would have endoscopic healing with AZA at week 102, and that 5% of patients would develop new lesions beyond week 52.
We considered a difference of 25% between the two groups to be clinically relevant and a sample size of 100 patients in each group would be needed to detect such a difference with a power of 80%. We expected a 20% drop-out rate due to AZA intolerance in the systematic AZA group and 15% in the endoscopy-driven AZA group. For the intention-to-treat analysis, the data from all randomized patients were incorporated. For the per-protocol analysis, only patients who had reached the week 102 endpoint or who had developed a clinical relapse prior to week 102 were included. For patients who prematurely stopped the study due to clinical recurrence, the last observed CDAI was carried forward. Patients who had prematurely stopped the study due to adverse events or compliance issues were excluded from the per-protocol analysis. All statistical analyses were performed using the IBM SPSS 22.0 software package (SPSS Inc., Chicago, IL, USA). 
Results
Study population
Due to slow recruitment, only 63 patients (26 male, median age 36 years) were randomized and included in the intention-to-treat analysis (Leuven n = 25, Athens n = 24, Prague n = 12, Bonheiden n = 2). Study inclusion was stopped in April 2012 after >6 years of recruitment. Four more patients were screened for the trial but were not eligible due to previous AZA-related pancreatitis (n = 1) or not being present at the randomization visit (n = 3). No patients were excluded based on the absence of risk factors or a less favourable TPMT profile. As depicted in Table 1 , the baseline characteristics of the patients in the two study arms were similar. Five patients in the systematic AZA group were on AZA at the moment of surgery compared with none of the patients in the endoscopy-driven AZA group (16 vs 0%, p = 0.053). In the per-protocol analysis, more males were randomized to the endoscopy-driven AZA group (60 vs 28%, p = 0.023). Baseline laboratory values were comparable in the two groups (Supplementary Table 1 ).
Patient flow and discontinuations
Of the 31 patients randomized to the endoscopy-driven AZA group, 11 and 3 initiated AZA at weeks 26 and 56, respectively. Twenty-one of the 63 patients (33%) withdrew from the study prematurely. Eight patients developed clinical recurrence, 6 of them prior to initiation of AZA (5 prior to the endoscopic evaluation at week 26 and one prior to week 52). Two patients randomized to the systematic AZA group developed clinical recurrence. These eight patients developing clinical recurrence were also included in the perprotocol analysis, containing 50 patients in total.
One patient refused to undergo the complete clinical follow-up in the study, and six patients refused to undergo the endoscopic evaluation at week 26 (n = 1) or week 102 (n = 5). Six patients discontinued the study prematurely due to adverse events while taking AZA, including leucopenia (n = 1), pancreatitis (n = 1), gastrointestinal intolerance (n = 2), weight gain (n = 1) and thyroid cancer (n = 1).
Primary and secondary endpoints
Neither the intention-to-treat analysis nor the per-protocol analysis revealed differences in the primary endpoint. As shown in Figure 2 , endoscopic remission was achieved by 50% of patients in the systematic AZA group and 42% in the endoscopy-driven AZA group (intention-to-treat analysis, p = 0.521). Six out of 14 patients in the endoscopy-driven AZA group achieved the primary endpoint at week 102 after initiation of AZA at weeks 26 (n = 11) or 52 (n = 3). Of the 10 patients in the endoscopy-driven AZA group who continued without CD-related therapy until week 102, 7 achieved the primary endpoint. Of the 8 patients with an i2 score and initiating AZA, 3 evolved to i0, 3 to i1, 1 remained at i2, and 1 evolved to i3 at week 102. Of the 2 patients with an i3 score and initiating AZA, 1 evolved to i2 and 1 remained at i3 at week 102. None of the secondary endpoints was significantly different between the two treatment arms, either in the intention-to-treat or in the per-protocol analysis ( Table 2) . As shown in Figure 3 , the evolution of CDAI throughout the study was comparable for the two study arms.
Of note, we did not observe a clearly increased risk of endoscopic recurrence with an increasing number of risk factors, either for the overall population or for the different treatment arms (Supplementary Figure 1) . Endoscopic recurrence was observed in 50% of patients with 1 risk factor, 56% of patients with 2 risk factors, 50% of patients with 3 risk factors and 75% of patients with 3 risk factors (linear-by-linear p = 0.625).
Adverse events
The adverse events that occurred during the trial are shown in Supplementary Table 2. Infections and skin lesions tended to occur more frequently in patients treated with AZA. One patient developed AZA-induced leucopenia and one patient developed AZA-induced pancreatitis. We did not observe a marked increase in liver tests. All 6 patients who withdraw from the trial due to adverse events were under AZA therapy at the time of withdrawal.
Discussion
In this postoperative CD recurrence trial the probability of endoscopic recurrence at 102 weeks was not lower in patients systematically treated with AZA postoperatively, compared with patients in whom AZA was only initiated upon endoscopic recurrence at week 26 or 52. Furthermore, the use of AZA was associated with known adverse events, including a wide range of infections, skin lesions, leucopenia and pancreatitis. Unfortunately, this study was prematurely stopped because of slow recruitment after enrolling only 32% of the intended sample size. Early postoperative endoscopic evaluation to guide further therapy seems appropriate, but larger studies are warranted.
The prevention of postoperative CD recurrence remains challenging to both patients and physicians. The vast majority of patients will develop endoscopic CD recurrence, which may eventually lead to symptomatic and surgical recurrence. 1 Although several clinical and histological predictors of postoperative CD recurrence have been proposed, the time frame between surgery and clinical recurrence is difficult to predict.
14 Furthermore, some patients remain symptom-free for several years after ileocolonic resection. Therefore, it is still unclear at which point patients should be offered medical therapy to prevent new CD complications or surgery.
Initiation of therapy only at the time of symptomatic recurrence is not ideal, since tissue damage may already be irreversible at that moment, eventually necessitating a new operative intervention. Several studies have evaluated the systematic introduction of Data are number of patients (%). CDAI, Crohn's disease activity index; ED-AZA, endoscopy-driven AZA; SBFT, small bowel follow-through; SYS-AZA, systematic AZA.
CD-related therapy immediately after surgery in high-risk patients. 15 Such an approach will most likely lead to a better clinical outcome by altering the natural history of the disease in the long term. However, several patients may be overtreated and facing unnecessary adverse events associated with CD-related therapy. Therefore, an endoscopydriven approach is currently routine practice at most IBD expert centres. An endoscopy is planned 6-12 months after surgery, and CD-related therapy is initiated upon proven endoscopic recurrence. This third option is valuable as long as the endoscopically observed lesions can still be healed without permanent tissue damage, a goal that may be reached with AZA. 16 Preliminary results of the POCER study suggest that immediate prophylactic therapy with adalimumab may be indicated in patients with high risk of postoperative recurrence. 11 There is no evidence to date indicating that systematic introduction of CD-related therapy postoperatively is superior to an endoscopy-driven approach. Our trial was not able to show superiority for the systematic introduction of AZA postoperatively.
In 2009, a Cochrane review reported the results of a meta-analysis including 27 published randomized controlled trials that assessed the effectiveness of medications to prevent the postoperative recurrence of CD. 17 Relative to placebo, the use of 18 performed a randomized controlled trial comparing AZA with mesalamine tablets for the prevention of clinical recurrence in patients with postoperative endoscopic CD, and showed that 63% of patients in the AZA group and 34% in the mesalamine group had a ≥1 point reduction of their Rutgeerts' endoscopic score compared with baseline after 1 year of treatment (p = 0.023). Especially when focusing on patients with more severe disease (i3-i4), this study showed that mesalamine has little to no effect on improvement of the endoscopic score. When comparing antibiotics with the combination of AZA and antibiotics, D'Haens et al. showed that AZA plus metronidazole led to significantly less severe endoscopic findings (i2-i4) at 12 months and a higher likelihood of 'no lesions' (22 vs 2%; p = 0.03). 19 Although AZA seems more efficacious than both placebo and mesalamine, its overall efficacy in preventing postoperative CD recurrence may not be sufficient in daily clinical practice. In the intention-to-treat analysis of this cohort, 50% of the 32 patients who received AZA did not achieve endoscopic remission and 38% did not achieve clinical remission (CDAI <150) at week 102. Another drawback is the relatively high rate of adverse events resulting in drug withdrawal. 18 In this cohort, 6 out of 46 patients had to discontinue AZA prior to week 102 due to leucopenia, pancreatitis, gastrointestinal intolerance, weight gain or thyroid cancer. Several other patients developed a minor infection or skin lesion under AZA.
In the last decade, anti-TNF agents have attracted a lot of interest in the prevention of postoperative CD recurrence. Already in 2006, IFX was shown to be efficacious in the prevention of postoperative clinical CD recurrence. 20 This case report was followed by numerous studies that nearly all demonstrated an impressive effect of the anti-TNF agents. 21 Regueiro et al. 9 randomized 24 CD patients after ileocaecal resection to receive IFX or placebo for 1 year, as preventive treatment within 4 weeks after surgery. Endoscopic recurrence at 1 year was only observed in 9 and 85%, respectively (p = 0.0006). Likewise, the histological recurrence rate at 1 year was significantly lower in the IFX group. Later, Yoshida et al. 22 studied 31 patients with CD who underwent ileocolonic resection and were randomly assigned postoperatively to IFX monotherapy or no treatment. After 1 and 3 years of follow-up, 100 and 93% of patients in the IFX group were in endoscopic remission, respectively, vs 69 and 56% in the control arm (p < 0.03). Based on these data, the placebo-controlled PREVENT trial was conducted evaluating the efficacy of IFX in preventing postoperative clinical recurrence at week 76. This study was discontinued prematurely since the primary endpoint of this trial was not met during an interim analysis. However, endoscopic recurrence rates at week 76 were significantly lower in the infliximab arm. 10 A few studies evaluating the efficacy of adalimumab also showed a role for this anti-TNF agent in preventing postoperative recurrence. In the recently published POCER trial, patients undergoing curative resection for CD received postoperative therapy with metronidazole for 3 months. 11 High-risk patients also received a purine analogue or, if intolerant, adalimumab. In the active care group, therapy could be upgraded after endoscopic assessment at month 6, when low-risk patients with endoscopic recurrence stepped up to purine analogues while high-risk patients on purine analogues stepped up to adalimumab every other week, and patients treated with adalimumab every other week were optimized to weekly administration. In the standard care group, no endoscopy was performed at month 6. All patients underwent endoscopy at 18 months and the primary endpoint was endoscopic recurrence at 18 months. In the active care group, endoscopic recurrence was significantly lower than in the standard care group (49 vs 67%, p = 0.028). However, stepup based on endoscopic assessment at 6 months brought 38% of patients with endoscopic recurrence into remission 1 year later. In high-risk patients, endoscopic recurrence rates at 18 months did not differ significantly between immediate postoperative adalimumab use and endoscopy-driven adalimumab use (43 vs 61%, p = 0.17).
11
One may speculate that patients with milder disease may benefit from postoperative therapy with azathioprine and do not require anti-TNF. However, a sub-analysis of our data taking into account the number of available risk factors did not show any difference between patients with more or less risk factors. However, our study was underpowered to draw any strong conclusion based on this observation.
The major limitation of this trial is the small patient sample due to slow recruitment. The impressive results with anti-TNF agents may certainly have influenced the recruitment of patients for this postoperative prevention trial based on AZA. However, the risks of adverse events with anti-TNF agents are certainly not negligible, and also its costs advocate a good stratification of patients at risk, including timely introduction of the anti-TNF agent.
In conclusion, we did not observe a benefit of systematic postoperative prophylactic therapy with AZA in patients at high risk of postoperative CD recurrence. Furthermore, several patients withdrew prematurely due to AZA-related adverse events. Based on the impressive results with anti-TNF in the postoperative setting, a similar approach should be performed to assess the superiority of systematic over endoscopy-driven anti-TNF therapy in the postoperative setting.
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